Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Richard W James"'
Autor:
Sarah Pedretti, Marie-Claude Brulhart-Meynet, Fabrizio Montecucco, Sandrine Lecour, Richard W James, Miguel A Frias
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218432 (2019)
PurposeHigh density lipoprotein (HDL) protects against myocardial infarction via mechanisms that remain unclear. STAT3 (signal transducer and activator of transcription 3) plays a key role in HDL-induced cardioprotection. In the heart, microRNAs (miR
Externí odkaz:
https://doaj.org/article/c399d7b48f8948e0a140efecba8b1a1e
Autor:
Sebastian Carballo, Anna Pfenniger, David Carballo, Nicolas Garin, Richard W James, François Mach, Dipen Shah, Brenda R Kwak
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 1, p 295 (2018)
Atrial fibrillation (AF) appears in the presence or absence of structural heart disease. The majority of foci causing AF are located near the ostia of pulmonary veins (PVs), where cardiomyocytes and vascular smooth muscle cells interdigitate. Connexi
Externí odkaz:
https://doaj.org/article/c5f0d7607d61467fa181097c7e2bbc0d
Autor:
Marie-Claude Brulhart-Meynet, Vincent Braunersreuther, Jonas Brinck, Fabrizio Montecucco, Jean-Christophe Prost, Aurelien Thomas, Katia Galan, Graziano Pelli, Sarah Pedretti, Nicolas Vuilleumier, François Mach, Sandrine Lecour, Richard W James, Miguel A Frias
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119664 (2015)
BackgroundNew evidence shows that high density lipoproteins (HDL) have protective effects beyond their role in reverse cholesterol transport. Reconstituted HDL (rHDL) offer an attractive means of clinically exploiting these novel effects including ca
Externí odkaz:
https://doaj.org/article/ff3c8d5ee6904f57aade61fef757dd33
Publikováno v:
American Journal of Clinical Nutrition, 108(6), 1283-1290. Oxford University Press
Background: Paraoxonase-1 (PON-1) is a high-density lipoprotein (HDL)-associated enzyme with antioxidative properties, which may protect against the development of cardiovascular disease. Alcohol consumption increases HDL cholesterol, but the extent
Autor:
Zoltan Pataky, Rodolphe Dusaulcy, Richard W. James, Nicolas Vuilleumier, Jacques Philippe, Miguel Frias, Valerie M. Schwitzgebel, Jonathan Sidibé, Florian Visentin, Aurélien Thomas, Yvan Gosmain, Marie-Claude Brulhart-Meynet
Publikováno v:
Physiological Reports
Physiological Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Physiological reports, vol. 9, no. 6, pp. e14786
Physiological reports, Vol. 9, No 6 (2021) P. e14786
Physiological Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Physiological reports, vol. 9, no. 6, pp. e14786
Physiological reports, Vol. 9, No 6 (2021) P. e14786
Beta cell failure is one of the most important features of type 2 diabetes mellitus (T2DM). High‐density lipoprotein (HDL) has been proposed to improve β‐cell function. However, the mechanisms involved in this process are still poorly understood
Autor:
Setor K Kunutsor, Robin P. F. Dullaart, Richard W. James, Stephan J. L. Bakker, Lyanne M. Kieneker
Publikováno v:
Kunutsor, S K, Kieneker, L M, Bakker, S J L, James, R W & Dullaart, R P F 2017, ' Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent-paraoxonase-1: The prospective cohort PREVEND study ', Metabolism, vol. 73, pp. 43-51 . https://doi.org/10.1016/j.metabol.2017.05.004
Metabolism, 73, 43-51. W B SAUNDERS CO-ELSEVIER INC
Metabolism, 73, 43-51. W B SAUNDERS CO-ELSEVIER INC
Objective. High-density lipoprotein cholesterol (HDL-C) is an established risk marker for cardiovascular disease and consistently associated with type 2 diabetes risk. Serum paraoxonase-1 (PON-1) - an anti-oxidant constituent of HDL - is inversely as
Autor:
Stephan J. L. Bakker, Richard W. James, Robin P. F. Dullaart, Lyanne M. Kieneker, Setor K Kunutsor
Publikováno v:
Kunutsor, S K, Kieneker, L M, Bakker, S J L, James, R W & Dullaart, R P F 2017, ' The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study ', Atherosclerosis . https://doi.org/10.1016/j.atherosclerosis.2017.06.353
ATHEROSCLEROSIS, 263, 219-226. ELSEVIER IRELAND LTD
ATHEROSCLEROSIS, 263, 219-226. ELSEVIER IRELAND LTD
Background and aims High-density lipoprotein cholesterol (HDL-C), an established risk marker for atherosclerotic cardiovascular disease (CVD), has been shown to be inversely and independently associated with incident hypertension. Paraoxonase-1 (PON-
Autor:
Richard W. James, Stephan J. L. Bakker, Charles E. Sparks, James P. Corsetti, Robin P. F. Dullaart
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine; Volume 8; Issue 9; Pages: 1357
Journal of Clinical Medicine, 8(9):1357. MDPI AG
Journal of Clinical Medicine, Vol 8, Iss 9, p 1357 (2019)
Journal of Clinical Medicine; Volume 8; Issue 9; Pages: 1357
Journal of Clinical Medicine, 8(9):1357. MDPI AG
Journal of Clinical Medicine, Vol 8, Iss 9, p 1357 (2019)
Paroxonase-1 (PON1) is a key enzyme that inhibits low-density lipoprotein oxidation and consequently atherogenesis. Here, we assessed whether low serum PON1 activity associates with incident cardiovascular disease (CVD) in subjects with high levels o
Autor:
Pamela S. Brewster, Chrysan J Mohammed, Tiana Sarsour, Andrew L. Kleinhenz, Steven T. Haller, Erin L. Crawford, Richard W. James, Prabhatchandra Dube, Yanmei Xie, Deepak Malhotra, Subhanwita Ghosh, David J Kennedy, Philip A. Kalra
Publikováno v:
Journal of Clinical Medicine
Volume 8
Issue 7
Journal of Clinical Medicine, Vol 8, Iss 7, p 1034 (2019)
Volume 8
Issue 7
Journal of Clinical Medicine, Vol 8, Iss 7, p 1034 (2019)
The burden of cardiovascular disease and death in chronic kidney disease (CKD) outpaces that of the other diseases and is not adequately described by traditional risk factors alone. Diminished activity of paraoxonase (PON)-1 is associated with increa
Autor:
Fabrizio Montecucco, Marie-Claude Brulhart-Meynet, Miguel Frias, Sandrine Lecour, Richard W. James, Sarah Pedretti
Publikováno v:
PLoS ONE
PLOS ONE, Vol. 14, No 6 (2019) P. e0218432
PLoS ONE, Vol 14, Iss 6, p e0218432 (2019)
PLOS ONE, Vol. 14, No 6 (2019) P. e0218432
PLoS ONE, Vol 14, Iss 6, p e0218432 (2019)
PurposeHigh density lipoprotein (HDL) protects against myocardial infarction via mechanisms that remain unclear. STAT3 (signal transducer and activator of transcription 3) plays a key role in HDL-induced cardioprotection. In the heart, microRNAs (miR